KYMR insider buying – Kymera Therapeutics, Inc.
12 insider purchases since 2016 worth $286.1M by 8 different insiders. Last 12 months: 1 purchases, $172.5M. Most recent filing: 2025-12-11.
Same time range as the chart above - each mark sits under the week of the trade. Circles = purchases (height = price paid, size = amount), red triangles = open-market sales of $50k+. Prices as reported, not adjusted for later stock splits.
Purchases are open-market buys (SEC Form 4, code "P") - insiders paying with their own money. Sales are open-market sales (code "S") of $50,000 or more; many sales are pre-planned (Rule 10b5-1) or made for taxes and diversification. Each row links to the original filing.
Bought, sold, still holding?
| Insider | Bought | First / last buy | Sold since 2016 | Holds now* | Status |
|---|---|---|---|---|---|
| BAKER FELIX Director | $172.5M 1× · 2,005,813 sh | 2025-12-11 2025-12-11 | – | 7,955,916 shares as of 2025-12-11 | Holds - never sold |
| Baker Bros. Advisors (GP) LLC Director | $28.8M 1× · 655,500 sh | 2025-06-30 2025-06-30 | – | 6,117,295 shares as of 2025-06-30 | Holds - never sold |
| BIOTECHNOLOGY VALUE FUND L P Director | $25.7M 2× · 554,266 sh | 2021-07-01 2022-05-20 | – | 294,632 shares as of 2024-06-28 | Holds - never sold |
| Biotechnology Value Trading Fund OS LP Director | $24.3M 2× · 589,934 sh | 2022-01-24 2025-06-30 | – | 3,282,852 shares as of 2026-06-25 | Holds - never sold |
| BIOTECHNOLOGY VALUE FUND II LP Director | $15.4M 2× · 586,532 sh | 2022-08-22 2023-01-11 | 1× · $173.7M last 2026-06-26 | 3,631,929 shares as of 2026-06-26 | Sold part |
| BVF INC/IL Director | $9.9M 2× · 380,309 sh | 2022-01-27 2022-05-05 | – | 230,637 shares as of 2022-06-17 | Holds - never sold |
| BVF II GP LLC Director | $5.3M 1× · 414,105 sh | 2023-11-02 2023-11-02 | – | 284,526 shares as of 2023-11-06 | Holds - never sold |
| BVF PARTNERS L P/IL Director | $4.2M 1× · 289,426 sh | 2022-05-26 2022-05-26 | – | 1,601,575 shares as of 2022-05-31 | Holds - never sold |
* Shares held after the insider's most recent SEC filing for this company (all share classes, direct and indirect). If an insider stops filing, later changes are not known.
Insider buying and selling by year
| Year | Purchases | Bought | Buyers | Sales | Sold |
|---|---|---|---|---|---|
| 2026 | 0 | – | – | 34 | $421.5M |
| 2025 | 3 | $215.3M | 3 | 22 | $54.9M |
| 2024 | 0 | – | – | 16 | $44.0M |
| 2023 | 2 | $6.6M | 2 | 1 | $3.8M |
| 2022 | 6 | $38.7M | 5 | 5 | $30.7M |
| 2021 | 1 | $25.6M | 1 | 25 | $56.8M |
Insider purchases
| Filed | Insider | Role | Shares | Avg price | Value | Holdings | Filing |
|---|---|---|---|---|---|---|---|
| 2025-12-11 | BAKER FELIX | Director | 2,005,813 | $86.00 | $172.5M | +33.7% | SEC |
| 2025-07-01 | Biotechnology Value Trading Fund OS LP | Director | 317,167 | $44.00 | $14.0M | +12.8% | SEC |
| 2025-06-30 | Baker Bros. Advisors (GP) LLC | Director | 655,500 | $44.00 | $28.8M | +12.0% | SEC |
| 2023-11-06 | BVF II GP LLC | Director | 414,105 | $12.80 | $5.3M | +18.5% | SEC |
| 2023-01-13 | BIOTECHNOLOGY VALUE FUND II LP | Director | 41,007 | $30.51 | $1.3M | +1.7% | SEC |
| 2022-08-23 | BIOTECHNOLOGY VALUE FUND II LP | Director | 545,525 | $26.00 | $14.2M | +28.2% | SEC |
| 2022-05-31 | BVF PARTNERS L P/IL | Director | 289,426 | $14.34 | $4.2M | +15.2% | SEC |
| 2022-05-24 | BIOTECHNOLOGY VALUE FUND L P | Director | 10,100 | $14.00 | $141,400 | +0.5% | SEC |
| 2022-05-09 | BVF INC/IL | Director | 250,000 | $19.46 | $4.9M | +14.0% | SEC |
| 2022-01-31 | BVF INC/IL | Director | 130,309 | $38.96 | $5.1M | +7.4% | SEC |
| 2022-01-26 | Biotechnology Value Trading Fund OS LP | Director | 272,767 | $37.76 | $10.3M | +17.6% | SEC |
| 2021-07-06 | BIOTECHNOLOGY VALUE FUND L P | Director | 544,166 | $47.00 | $25.6M | +48.6% | SEC |
Insider sales
| Filed | Insider | Role | Shares | Avg price | Value | Type | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-04 | Adams Brian | Officer | 6,371 | $116.83 | $744,297 | Sale | SEC |
| 2026-07-07 | Mainolfi Nello | CEO | 50,000 | $119.00 | $6.0M | Sale | SEC |
| 2026-07-02 | Mainolfi Nello | CEO | 80,000 | $115.30 | $9.2M | Sale | SEC |
| 2026-07-02 | Goodman Noah | Officer | 3,389 | $114.29 | $387,329 | Sale | SEC |
| 2026-07-02 | Jacobs Bruce N. | CFO | 77,109 | $114.97 | $8.9M | Sale | SEC |
| 2026-06-30 | Booth Bruce | Director | 31,283 | $109.48 | $3.4M | Pre-planned (10b5-1) | SEC |
| 2026-06-30 | Booth Bruce | Director | 513,245 | $110.01 | $56.5M | Pre-planned (10b5-1) | SEC |
| 2026-06-26 | BIOTECHNOLOGY VALUE FUND II LP | Director | 1,630,658 | $106.50 | $173.7M | Sale | SEC |
| 2026-06-25 | Goodman Noah | Officer | 5,000 | $114.00 | $570,000 | Sale | SEC |
| 2026-06-25 | Booth Bruce | Director | 285,684 | $121.86 | $34.8M | Pre-planned (10b5-1) | SEC |
| 2026-06-25 | Booth Bruce | Director | 398,765 | $110.31 | $44.0M | Pre-planned (10b5-1) | SEC |
| 2026-06-22 | Goodman Noah | Officer | 2,500 | $99.00 | $247,500 | Sale | SEC |
| 2026-06-22 | Booth Bruce | Director | 31,798 | $103.75 | $3.3M | Pre-planned (10b5-1) | SEC |
| 2026-06-22 | Booth Bruce | Director | 478,198 | $94.72 | $45.3M | Pre-planned (10b5-1) | SEC |
| 2026-05-27 | Chadwick Jeremy G | Officer | 17,184 | $79.92 | $1.4M | Sale | SEC |
Showing the latest 15 of 103 sales of $50,000+ since 2016.
Compiled automatically from public SEC filings. Not investment advice. Get every new insider purchase in the daily report.
Get every new insider purchase the day it's filed
Daily report with all SEC insider buys, cluster buys, company events and the crypto money-flow radar.
Get started free